Skip to main content

Table 3 Associations of TGFBR2 and IL12B SNPs with overall survival in discovery and replication samples

From: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

Breast cancer patients TGFBR2 rs1367610 (G > C) IL12B rs2546892 (G > A ) IL12B rs2853694 (A > C)
Cases, number Events, number HR (95% CI) P -value Cases, number Events, number HR (95% CI) P -value Cases, number Events, number HR (95% CI) P -value
Discovery             
ER-negative and received chemotherapya 1499 267 1.54 (1.22, 1.95) 3.08 × 10−4 1499 267 1.50 (1.21, 1.86) 1.81 × 10−4 1499 267 0.73 (0.61, 0.87) 3.67 × 10−4
  I 2c = 86.7%; P heterogeneityd = 5.00 × 10−4 I 2c = 78.5%; P heterogeneityd = 9.50 × 10−3 I 2c = 75.9%; P heterogeneityd = 0.016
Replication             
ER-negative and received chemotherapy             
 BCAC Asian studiesa 372 42 2.18 (0.85, 5.60) 0.105 372 42 0.62 (0.30, 1.26) 0.187 372 42 1.03 (0.63, 1.67) 0.919
 POSH studyb 127 62 1.59 (0.94, 2.69) 0.084 127 62 1.09 (0.67, 1.78) 0.715 127 62 0.87 (0.62, 1.22) 0.408
Combined replication             
ER-negative and received chemotherapy 499 104 1.71 (1.08, 2.72) 0.022 499 104 0.91 (0.61, 1.36) 0.659 499 104 0.92 (0.69, 1.21) 0.535
  I 2c = 0%; p heterogeneityd = 0.567 I 2c = 40.4%; P heterogeneityd = 0.20 I 2c = 0%; P heterogeneityd = 0.577
Combined overall             
ER-negative received adjuvant chemotherapy 1998 371 1.57 (1.28, 1.94) 2.05 × 10−5 1998 371 1.11 (0.70, 1.76) 0.653 1998 371 0.78 (0.67, 0.90) 8.00 × 10−4
  I 2c = 0%; P heterogeneityd = 0.781 I 2c = 68.3%; P heterogeneityd = 0.04 I 2c = 6.4%; P heterogeneityd = 0.344
  1. aHR adjusted for age of diagnosis, tumor size, tumor grade, node status and principal components to account for population substructure and stratified by study. bHR adjusted for age of diagnosis, tumor size, tumor grade, node status and metastasis status. c I 2 index derived on the basis of effect estimate and variance in each study. d P-value for test of heterogeneity between studies using the DerSimonian-Laird test. TGFBR2, transforming growth factor, beta receptor II; SNP, single nucleotide polymorphism; HR, hazard ratio; ER, estrogen receptor; BCAC, Breast Cancer Association Consortium; IL12B, interleukin 12B; CI, confidence interval; and POSH, Prospective Study of Outcomes in Sporadic versus Hereditary Breast Cancer.